Recon: Moderna cleared to increase vaccine doses per vial; FDA investigating J&J vaccine mix-up at Emergent facility

• Fauci says US may not need AstraZeneca COVID-19 vaccine (Reuters)
• FDA allows Moderna to put more coronavirus vaccine doses in each vial (Politico) (Reuters) (FDA)
• FDA Probes Cause of Failed Johnson & Johnson Covid-19 Vaccine Batch (WSJ)
• Why the Biden administration might not want to be content with just an acting FDA commissioner (Endpoints)
• Johnson & Johnson expands COVID vaccine trial to include adolescents (The Hill)
• FDA Okays New Indication for Alirocumab in Homozygous FH (Medscape) (FDA)

• EU countries agree to share 'solidarity vaccines' with states in need (Reuters)
• EU cuts Austria, Slovenia and Czech Republic from extra vaccine deal (FT)
• Australia probes if blood clot case linked to AstraZeneca vaccine (Reuters)
• Netherlands halts use of AstraZeneca vaccine for people under 60 (Reuters)
• UK regulator found total of 30 cases of blood clot events after AstraZeneca vaccine use (Reuters)
• China Sinovac says it reached two billion doses annual capacity for COVID-19 vaccine (Reuters)
• Measles resurgent in Congo eight months after epidemic declared over (Reuters)

• Trump-Touted Drug Lives On as Covid Therapy Despite Trial Flops (Bloomberg)
• ‘Where the magic happens’ — inside BioNTech’s innovative vaccine plant (FT)
• CDC: Vaccinated Americans can now travel (Politico)
• $1.3 Billion Johnson & Johnson COVID-19 Vaccine Development Contract Contains Broad Redactions Relating to Public’s Rights in Inventions (KEI)
• Nigeria aims to get 70 million J&J COVID-19 vaccines through African Union (Reuters)
• India AstraZeneca shot delay could be 'catastrophic' for Africa -health official (Reuters)
• Backed by Millions in Public and Private Cash, Rapid Covid Tests Are Coming to Stores Near You (KHN)

• GlaxoSmithKline offloads royalty rights for 2 cancer drugs in $342M windfall it will use to finance consumer spinoff (Endpoints)
• Roche/Novartis: rivals play king of the pill (FT)
• Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data (Fierce)
• Regulators Share Pandemic’s CMC Impact at CASSS Japan Forum; Guidance Output Continues Apace in Q1 2021 (IPQ)
• Gilead expands AbCellera antibody discovery pact to access rival to Regeneron's mouse platform (Fierce)
• Pfizer breaks ground on sterile injectables plant in Michigan, plans to add around 450 jobs to the region (Endpoints)
• Merck KGaA lands rights to 3rd F-star oncology bispecific antibody (Fierce)
• Proteomics company SomaLogic to chase $1.2B public valuation through SPAC deal (Fierce)
• Alloy Therapeutics nabs a $75M series C to sow more seeds into the biotech ecosystem (Fierce)
• Alcami appoints new CEO in Patrick Walsh, the executive who helped lead the CDMO's predecessor company (Endpoints)
• It's time: After 19 years, legendary Koch Institute director Tyler Jacks passes the torch to Matthew Vander Heiden (Endpoints)
• Stuart Lipton offers a new possible reason why all the Alzheimer's drugs have failed (Endpoints)
• United Therapeutics bags a new OK on Tyvaso, with blockbuster expectations; Gilead goes back to AbCellera's well with a set of fresh targets (Endpoints)
• After name change and dropped IPO, IN8bio tries again to boost its cancer pipeline (Fierce)

• FDA cites potential infection risks with reusable urological endoscopes (Fierce) (FDA)
• Bluestar's blood test nets FDA breakthrough label to screen for pancreatic cancer after sudden cases of diabetes (Fierce)
• Quest sells minority share of Q2 Solutions for $760M (MedtechDive)

• Bills, Bills, Bills: Congress Advances Bills to Address Drug Competition (FDA Law Blog)
• Mitsubishi Tanabe Wins US Patent Suit on Canagliflozin (PharmaJapan)
• Vagisil Maker Gets Rival's 'Vagisert' TM Blocked At TTAB (Law360)
• Big Pharma Tells Justices To Keep Assignor Estoppel (Law360)
• Illumina Agrees To Delay $8B Grail Deal During FTC Challenge (Law360)
• Bristol Myers Squibb Settles Medicaid Rebate Suit For $75M (Law360)